Vividion Therapeutics Inc.

4 trials 2 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

4 Countries active

0 Unique IMPs

100% Results reported

Phase I

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

DNA mismatch repair protein gene mutation 1

All trials

4 total

A PHASE 1/1B, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC… Pending

2025-522148-42-00 Phase I 1 country
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli… Recruiting

2023-506199-28-00 Phase I 1 country
A Phase I Study of VVD-133214 Alone and in Combination in Participants with Advanced Solid Tumors Recruiting

2023-503170-20-01 Phase I 4 countries
A First in Human open label study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activi… Ended

2023-508386-32-00 Phase I 1 country

Showing 1–4 of 4 trials

← All sponsors A–Z